INSM

Insmed
D

INSM

73.350
USD
-0.08
(-0.11%)
Market Closed
Volume
86,127
EPS
-6
Div Yield
-
P/E
-13
Market Cap
13,276,302,322
Related Instruments
A
ALKS
-0.970
(-2.97%)
31.660 USD
AMGN
AMGN
4.42
(1.45%)
310.04 USD
A
ARWR
-0.610
(-4.81%)
12.070 USD
BIIB
BIIB
-0.630
(-0.48%)
130.690 USD
C
CRBP
-0.28000
(-5.37%)
4.93000 USD
GILD
GILD
0.450
(0.40%)
112.380 USD
L
LGND
-5.340
(-4.93%)
103.020 USD
REGN
REGN
-14.36
(-2.30%)
610.88 USD
VRTX
VRTX
0.63
(0.13%)
484.01 USD
More
News

Title: Insmed

Sector: Healthcare
Industry: Biotechnology
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatmentof Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterialhypertension.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.